Curated news and analysis on clinical trials, drug approvals, and medical research.
South Korea has approved fast-track drug listing for rare disease treatments, reducing the insurance coverage process from 240 days to 100 days. The reform includes post-listing effectiveness evaluations and flexible pricing agreements, aiming to improve patient access to innovative treatments amid ongoing budget concerns.
The global GMP consumables market is projected for significant growth through 2035, driven by expansion in biologics, cell and gene therapies, and mRNA vaccine manufacturing. The market will shift from basic contamination control to enabling advanced therapeutic production with specialized single-use systems. Growth will be supported by regulatory standards, supply chain resilience, and increasing biosimilar production in Asia-Pacific and emerging markets.
Pharmaceutical companies are delaying European drug launches due to uncertainty over U.S. pricing policies under President Trump. New drug launches in EU markets fell 35% following Trump's executive order on international reference pricing. Companies fear lower European prices could undermine their ability to maintain higher prices in the $700 billion U.S. market.
A multinational survey shows bridging therapy is used for over 85% of multiple myeloma patients awaiting CAR T-cell therapy, with proteasome inhibitors being the most common approach. Most centers lack standardized protocols and typically bridge patients for 1-2 months, with regimen selection driven primarily by prior therapy history and disease burden.
Researchers have developed a machine learning method called STRUCTURES25 that enables precise quantum chemistry calculations for large drug-like molecules using an orbital-free approach. The breakthrough solves a decades-old stability problem in computational chemistry while reducing computational requirements. This advancement could accelerate drug discovery and materials science research.
The FDA has accepted Praxis Precision Medicines' NDA for relutrigine with priority review and set a PDUFA target date of September 27, 2026. The therapy targets SCN2A and SCN8A developmental and epileptic encephalopathies and could become the first approved treatment for these rare conditions. The company has bolstered its cash position to support commercial launch preparations.
The FDA has granted Priority Review for lirafugratinib, an FGFR2 inhibitor for second-line cholangiocarcinoma treatment, with a PDUFA date of September 27, 2026. Clinical trial data showed a 46.5% objective response rate and 11.8-month median duration of response. The therapy demonstrated a manageable safety profile with lower rates of common FGFR inhibitor side effects.
Clinical trials take 10-15 years and cost $1-2 billion from discovery to approval, progressing through four phases from safety testing to real-world monitoring. These studies face challenges including high costs, regulatory oversight, and participant recruitment while new technologies are transforming trial design. Illinois faces a shortage of Phase I clinical trial facilities despite local companies conducting over 50 such trials annually.
Biodexa Pharmaceuticals has licensed MTX240, a Phase 1-ready molecular glue therapy for gastrointestinal stromal tumors from Otsuka. The drug demonstrated preclinical efficacy in resistant tumors and is eligible for orphan drug exclusivity, with clinical trials planned by year-end.
Multiple Indian pharmaceutical companies including Zydus, Glenmark, Dr. Reddy's, and Alkem have launched semaglutide versions following patent expiry, dramatically reducing prices and expanding access. Companies are competing on both price and innovative delivery systems, with monthly therapy costs now ranging from Rs 1,300 to Rs 4,200. This development could significantly impact diabetes and obesity treatment in India, where over 100 million people live with diabetes.
Ataraxis AI has launched Ataraxis Breast CTX, an AI test that predicts individualized chemotherapy benefit for breast cancer patients. The tool uses digital pathology and clinical data to estimate patient-level outcomes with and without chemotherapy, moving beyond population averages. The test has been validated across studies involving over 10,000 patients and is now available through CLIA-certified laboratories.
A study finds nearly half of melanoma patients receiving BRAF or MEK inhibitors develop hypertension or cardiac dysfunction. Moderate to severe cardiac issues appear within 4 weeks and only in patients with medium or higher baseline risk. Higher baseline NT-proBNP levels are associated with increased cardiac dysfunction risk.
Viridian Therapeutics reported positive Phase 3 results for elegrobart in thyroid eye disease, showing significant proptosis reduction and diplopia resolution. The company plans a BLA submission in Q1 2027 and has another IGF-1R inhibitor, veligrotug, under FDA Priority Review with a June 2026 decision date.
The artificial intelligence in drug discovery market is projected to grow from USD 3.25 billion in 2026 to USD 10.29 billion by 2031, representing a 25.94% CAGR. AI technologies are accelerating drug discovery timelines, reducing costs, and improving success rates through advanced analytics and machine learning. North America leads market adoption while Asia-Pacific emerges as a high-growth region driven by expanding biotechnology sectors.
Tempest Therapeutics reported 2025 financial results showing $7.7 million in cash and highlighted clinical progress including 100% complete response rate in TPST-2003 CAR-T trial and multiple FDA designations for amezalpat in hepatocellular carcinoma. The company completed strategic CAR-T asset acquisition and plans Phase 2b registrational study for its lead program in 2026.
The National Institute of Allergy and Infectious Diseases has been instructed to remove "biodefense" and "pandemic preparedness" language from its website, signaling a major shift away from these research priorities. NIH leadership says the institute will now focus on current infectious diseases and basic immunology rather than predicting future threats. Public health experts warn this could leave the U.S. less prepared for future health emergencies.
New research reveals that ultra-marathon running damages red blood cells, making them less flexible and accelerating their breakdown. The study found this damage increases with race distance and could potentially lead to anemia. The findings may also help improve blood storage practices for medical transfusions.
Roche Holding AG shares show potential undervaluation despite strong returns, with DCF models suggesting 59% upside. The pharmaceutical giant trades at P/E ratios below fair value estimates while maintaining solid financial performance and dividend growth. Recent pipeline developments and product innovations support long-term growth prospects.
Oramed Pharmaceuticals experienced a 57.8% surge in short interest in January 2024, reaching 644,912 shares. The company continues to navigate challenges following the failure of its Phase 3 oral insulin trial in early 2023, which caused its stock to plummet over 70%. Oramed maintains focus on its proprietary oral drug delivery technology while exploring strategic alternatives.
AI-powered clinical alerts improved heart valve disease treatment rates by 40% in a multicenter trial involving 35 hospitals. The system increased timely interventions and reduced disparities in care access across different patient populations.
